| 2.03 -0.01 (-0.49%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.5 | 1-year : | 2.77 |
| Resists | First : | 2.14 | Second : | 2.37 |
| Pivot price | 2.15  |
|||
| Supports | First : | 1.77 | Second : | 1.48 |
| MAs | MA(5) : | 2.08 |
MA(20) : | 2.08 |
| MA(100) : | 1.98 |
MA(250) : | 1.93 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 37.3 |
D(3) : | 46.7 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 2.41 | Low : | 1.54 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SEER ] has closed above bottom band by 12.0%. Bollinger Bands are 11.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.07 - 2.09 | 2.09 - 2.1 |
| Low: | 1.97 - 2 | 2 - 2.01 |
| Close: | 2 - 2.04 | 2.04 - 2.07 |
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Thu, 15 Oct 2026
Seer, Inc. News — NASDAQ:SEER - TradingView
Wed, 23 Sep 2026
A Singapore study of 10,000 people will share early protein findings - Stock Titan
Wed, 23 Sep 2026
Seer and Nanyang Technological University to Present Early - GlobeNewswire
Mon, 21 Sep 2026
Seer Announces Leadership Transition in Finance Roles - Quiver Quantitative
Mon, 03 Aug 2026
Seer to Report Second Quarter 2026 Financial Results on August 11, 2026 - Yahoo Finance
Thu, 30 Jul 2026
Seer Confirms Receipt of Further Revised Unsolicited - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 14.6 (%) |
| Held by Institutions | 50.6 (%) |
| Shares Short | 109 (K) |
| Shares Short P.Month | 146 (K) |
| EPS | -1.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.07 |
| Profit Margin | 0 % |
| Operating Margin | -543 % |
| Return on Assets (ttm) | -15.3 % |
| Return on Equity (ttm) | -26.5 % |
| Qtrly Rev. Growth | -23.4 % |
| Gross Profit (p.s.) | 0.12 |
| Sales Per Share | 0.25 |
| EBITDA (p.s.) | -1.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -1.67 |
| PEG Ratio | 0 |
| Price to Book value | 0.49 |
| Price to Sales | 7.9 |
| Price to Cash Flow | -2.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|